Shares of Mankind Pharma Ltd were trading in the red today even as the pharma firm said its board has approved the closure of ...

In a meeting held on December 20, 2024, the Fund Raising Committee of the company had approved the issue of 1.19 crore equity ...

The equity shares will be allotted to the eligible QIBs at an issue price of ₹2,520 per share - a price which includes a ...

Mankind Pharma has launched a Rs 3,000 crore QIP to fund its acquisition of Bharat Serums and Vaccines. The company has seen ...

Mankind Pharma said that its board has approved the closure of the issue for the qualified institutions placement of equity shares of the company on Thursday, 19 December 2024.

Consequent to the aforesaid allotment, the paid-up share capital of the Company has increased from Rs 40,06,62,138 consisting 40,06,62,138 equity shares to Rs 41,25,66,899 consisting 412566899 equity ...

The pharma company has acquired 100% stake in BSV for ₹13,768 crore, to be funded through a combination of internal accruals ...

Mankind Pharma aims to become a debt-free company within the next three years, top executive told NDTV Profit earlier.

The indicative issue price for the QIP is expected to be approximately ₹2,520 per share, which could lead to an equity ...

Mankind Pharma, India’s fourth-largest pharmaceutical company by domestic sales, has officially launched its Rs 3,000 crore ...

The QIP opened on December 16, 2024, with Mankind Pharma keeping the option to offer a discount of up to 5% on the floor ...

The renewed foreign fund outflows from the India markets could push investors to turn cautious or risk-averse.